Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 32

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 32
---
 and emerging science trends on our clinical programs.

The Science Committee is currently composed of five directors: Dr. Berger, Dr. Higgins, Dr. Lacey, Dr. Perlman and Dr. Ribas. Dr. Parsey served as a member of the Science Committee during the fiscal year ended December 31, 2024 but was replaced by Dr. Berger in February 2025 in connection with Dr. Parsey's departure from our Board. Dr. Perlman is the chair of the Science Committee.

Stockholder Communications with The Board of Directors

Stockholders and any interested party may direct correspondence to the Board or an individual director, including Dr. Kaneko, our lead independent director, to our Corporate Secretary at our principal executive offices at 3928 Point Eden Way, Hayward, CA 94545. The Corporate Secretary will review all correspondence and will forward the communications on to the relevant individual director or the whole Board; however, the Corporate Secretary generally will not forward communications that are primarily solicitations for products or services, matters of a personal nature that are not relevant for stockholders, matters that are of a type that render them improper or irrelevant to the functioning of the Board, or requests for general information about Arcus.

#### Code of Conduct and Ethics
We have adopted the Arcus Biosciences, Inc. Code of Conduct and Ethics that applies to all officers, directors and employees. The Code of Conduct and Ethics is available on our website at www.arcusbio.com. If we make any substantive amendments to the Code of Conduct and Ethics or grant any waiver from a provision of the Code to any executive officer

<div align='center'>16.</div>

or director, Arcus will promptly disclose the nature of the amendment or waiver on its website or in a Current Report on Form 8-K.

#### Corporate Governance Guidelines
The Board adopted Corporate Governance Guidelines to document the governance practices we follow and to assure that the Board will have the necessary authority and practices in place to review and evaluate our business operations as needed and to make decisions that are independent of our management. The guidelines are also intended to align the interests of directors and management with those of Arcus’s stockholders. The Corporate Governance Guidelines set forth the practices the Board intends to follow with respect to Board composition and selection, Board meetings and involvement of senior management, Chief Executive Officer performance evaluation and succession planning and Board committees and compensation. The Corporate Governance Guidelines, as well as the charters for each committee of the Board, may be viewed at www.arcusbio.com.